2009 Hot Markets -- Thawing In a Frigid Economy
Ranked No. 4 is medical products/pharmaceuticals
($414B, +3%; with $12.3B to print, +2%). Pharmaceuticals and wellness ($7.8B to print, -8%) are anything but healthy, as patents expire and generics prevail. Packaging, point-of-purchase (POP), ROP and bind-in placements are in decline with the dearth of new medicines. Medical products and biotechnology ($4.5B to print, +12%) will counter traditional pharma with a flourish of new products. It’s where we must be in the waiting room.
Vincent Mallardi, C.M.C., is a the chairman of the Printing Brokerage/Buyers Association International (PBBA) and is a Certified Management Consultant in the paper, printing and converting industries. He is also an adjunct professor in economics. Contact him via email at vince@pbba.org
